Directly observed therapy [7]

Lancet

Volumn 349, Issue 9062, 1997, Pages 1399-1400

  Volmink, J ^a   Garner, P ^a  

^a LIVERPOOL SCHOOL OF TROPICAL MEDICINE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

COST EFFECTIVENESS ANALYSIS; DISEASE MANAGEMENT; HEALTH ECONOMICS; HUMAN; INTERSTITIAL NEPHRITIS; LETTER; PRIORITY JOURNAL; TUBERCULOSIS; COST BENEFIT ANALYSIS; DRUG THERAPY; ECONOMICS; PATIENT COMPLIANCE; STANDARD; UNITED NATIONS;

TUBERCULOSTATIC AGENT;

ANTITUBERCULAR AGENTS; COST-BENEFIT ANALYSIS; DRUG THERAPY; HUMANS; PATIENT COMPLIANCE; TUBERCULOSIS; UNITED NATIONS;

EID: 0030612354     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(05)63244-8     Document Type: Letter

References (2)

1. K Morris WHO sees DOTS Lancet 349 1997 857
2. J Volmink P Garner Promoting adherence to tuberculosis treatment P Garner H Gelband P Olliaro R Salinas J Vomink D Wilkinson Infectious diseases module of the Cochrane database of sysematic reviews (updated April 15, 1997). The Cochrane Library 1997 Update Software Oxford